February 4, 2020
MSD and Kissei Pharmaceutical said on February 3 that the distribution rights for the US giant’s once weekly DPP-4 inhibitor Marizev Tablets (omarigliptin) will be transferred to the Japanese firm in April. The details of the deal were not disclosed...read more